Gene therapies are changing the way we treat diseases by targeting the cause of a disease directly at the DNA level, rather than...

By IGT Director of Health Policy & Advocacy John Feore This month, I had the opportunity to participate in the American Society of Cell...

On June 26th, the Institute for Gene Therapies hosted its second Congressional Briefing focused on the promise of gene therapy, its...

Lauren Holder, Huntington’s Disease Patient Advocate and member of the Institute for Gene Therapy Patient Advocacy Advisory Council,...

Patients, researchers, and other key stakeholders are weighing in on the importance of the Medicaid VBPs for Patients Act, or the MVP Act...

Today, the Institute for Gene Therapies (IGT) sent a letter to Congress applauding Representatives Brett Guthrie (R-KY), Anna Eshoo...

By Nate Plasman This February, I had the opportunity to travel to Capitol Hill to participate in the Institute for Gene Therapy’s...

By IGT Chairman Erik Paulsen As more breakthrough gene therapies are developed and brought to market, a critical element in bringing...

On February 21, the Institute for Gene Therapies hosted a panel discussion on the science of gene therapy, its impact on patients and...

IGT Scientific, Academic, and Medical Council Chair Dr. Donna Christian-Christensen recently wrote an opinion piece for Inside Sources,...